A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
News|Videos|May 7, 2024
ARVO 2024: SriniVas Sadda, MD, discusses his vision for ARVO as new president, advancing vision science research, and impact of annual meetings
Author(s)David Hutton, Sheryl Stevenson
Sadda discusses his goals for ARVO, focusing on enhancing the organization's role in promoting scientific exchange in vision research. He underscores the significance of the annual meetings for networking and driving innovation in ophthalmology.
Advertisement
Advertisement
SriniVas R. Sadda, MD, discusses his upcoming term as ARVO president, focusing on the organization's mission to foster global collaboration in research, the challenges of maintaining funding for vision science research, and how ARVO's annual meetings have been crucial in building relationships and inspiring innovation in ophthalmology.
Related to this article
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Advertisement
Advertisement